Navigation Links
Protalix BioTherapeutics Announces Public Offering of Common Stock
Date:10/7/2007

ned from UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, NY 10171, Toll Free: (888) 827-7275.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based protein expression system, ProCellEx(TM). ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix has initiated enrollment and treatment of patients in its pivotal phase III clinical trial of its lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a lysosomal storage disorder in humans. The final design of the pivotal phase III clinical trial is based on an agreement reached by Protalix with the United States Food and Drug Administration, through its Special Protocol Assessment (SPA). Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our tech
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... world of the 21st century owes a tremendous amount ... finely control the flow of electrical charges using increasingly ... continue to race ahead, researchers at the University of ... by replacing electricity with light. "Looking at the ...
... Springboard Enterprises has over a decade of experience ... potential investors and corporate partners.  Today they launch ... to fast track the growth of the best ... from around the world. The search is on ...
... and AMSTERDAM, Feb. 23, 2012   Rubicon Genomics, ... pre-analytical processes to improve the capabilities and ... today announced a clinical supply agreement with ... whole genome RNA amplification technology.  Agendia will ...
Cached Biology Technology:Penn researchers build first physical 'metatronic' circuit 2Penn researchers build first physical 'metatronic' circuit 3Penn researchers build first physical 'metatronic' circuit 4The Search Is On for the Next Big Life Science Innovation 2The Search Is On for the Next Big Life Science Innovation 3Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3
(Date:4/17/2014)... years ago, Katia Silvera , a postdoctoral scholar at ... a field trip in a mountainous area in central Panama ... before. , Unable to identify it, they contacted German Carnevali, ... to be an unnamed species. So Carnevali recently named it ... the genus name, comprising about 40 species in the world. ...
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... antibacterial protein targeted against E. coli O157:H7 may offer ... infections, as demonstrated in a study published in the ... Results in an animal model of E. coli ... by AvidBiotics, Inc., could prevent or treat E. ...
... YORK, November 20, 2011 In a new study scientists ... of smell can be improved. The new findings, published online ... ways to reverse the loss of smell due to aging ... senses, explains Donald A. Wilson, PhD, professor of child and ...
... in Nature Medicine describes how different types of immune ... regrow bone and tissue, bringing into sharp focus the ... cell regeneration. The study, conducted at the Center ... Dentistry of USC, examined how mice with genetic bone ...
Cached Biology News:Targeted antibacterial proteins may offer antibiotic alternative 2Targeted antibacterial proteins may offer antibiotic alternative 3A failing sense of smell can be reversed 2
Polyclonal Antibody to CLAN...
Request Info...
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biology Products: